Effect of Single vs Multiple Prophylactic Antibiotic Doses on PJI Following Primary THA in Patients With OA
Launched by SOREN OVERGAARD · Sep 3, 2022
Trial Information
Current as of July 08, 2025
Active, not recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effect of giving either one dose or multiple doses of antibiotics to prevent infections in patients undergoing total hip replacement surgery due to osteoarthritis. The goal is to find out if a single dose of antibiotics given within 24 hours before or after surgery is just as effective as giving several doses. This research involves around 20,000 patients across various hospitals in Denmark.
To participate in this trial, you need to be an adult between the ages of 65 and 74 who is having a total hip replacement surgery for osteoarthritis. However, if your surgery is due to a fracture or a bone tumor, you won't be eligible. If you join the study, you'll be randomly assigned to receive either the single or multiple doses of antibiotics, and researchers will monitor you to see if you develop any infections after your surgery. This trial aims to improve treatment options and ensure the best outcomes for patients undergoing this type of surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. All patients receiving a primary Total Hip Arthroplasty (THA) due to primary and secondary causes of osteoarthritis
- Exclusion Criteria:
- • 1. Patients receiving a primary THA due to either acute or sequelae of proximal femoral or acetabular fractures
- • 2. Patients receiving a primary THA due to bone tumor or metastasis
About Soren Overgaard
Soren Overgaard is a dedicated clinical trial sponsor with a commitment to advancing medical research and improving patient outcomes. With extensive expertise in clinical development and a focus on innovative therapeutic solutions, Overgaard leads initiatives that prioritize patient safety and regulatory compliance. The organization is renowned for its collaborative approach, working closely with healthcare professionals, regulatory bodies, and research institutions to facilitate the efficient design and execution of clinical studies. Through rigorous methodologies and a commitment to scientific integrity, Soren Overgaard strives to contribute to the future of healthcare by bringing new therapies to market and enhancing the understanding of various medical conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Aalborg, , Denmark
Aalborg, , Denmark
Aarhus C, , Denmark
Aarhus, , Denmark
Aarhus, , Denmark
Brøndby, , Denmark
Copenhagen Nv, , Denmark
Copenhagen ø, , Denmark
Esbjerg, , Denmark
Farsø, , Denmark
Farum, , Denmark
Frederikshavn, , Denmark
Grindsted, , Denmark
Hellerup, , Denmark
Hellerup, , Denmark
Herlev, , Denmark
Herning, , Denmark
Hillerød, , Denmark
Holbæk, , Denmark
Horsens, , Denmark
Hvidovre, , Denmark
Kongens Lyngby, , Denmark
Kruså, , Denmark
Køge, , Denmark
Næstved, , Denmark
Odense, , Denmark
Randers, , Denmark
Ringsted, , Denmark
Rønne, , Denmark
Silkeborg, , Denmark
Søborg, , Denmark
Vejle, , Denmark
Vejle, , Denmark
Viborg, , Denmark
Aabenraa, , Denmark
Nykøbing Falster, , Denmark
Patients applied
Trial Officials
Armita A Abedi, MD
Principal Investigator
Copenhagen University Hospital Bispebjerg, Department of Orthopaedic Surgery and Traumatology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials